The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth
Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., & Leder, P. (1996) · Cell · doi:10.1016/s0092-8674(00)81069-7 · Cited by 1,070
Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3
Colvin, J. S., Bohne, B. A., Harding, G. W., McEwen, D. G., & Ornitz, D. M. (1996) · Nature Genetics · doi:10.1038/ng0496-390 · Cited by 873
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637
Chesi, M., Nardini, E., Lim, R. S. C., Smith, K. D., Kuehl, W. M., & Bergsagel, P. L. (1998) · Blood · doi:10.1182/blood.v92.9.3025 · Cited by 572
Naski, M. C., Wang, Q., Xu, J., & Ornitz, D. M. (1996) · Nature Genetics · doi:10.1038/ng0696-233 · Cited by 498
Naski, M. C., Colvin, J. S., Coffin, J. D., & Ornitz, D. M. (1998) · Development · doi:10.1242/dev.125.24.4977 · Cited by 420
FGFR activation in skeletal disorders: Too much of a good thing
Webster, M. (1997) · Trends in Genetics · doi:10.1016/s0168-9525(97)01131-1 · Cited by 317
Stec, I., Wright, T. J., van Ommen, G.-J. B., de Boer, P. A. J., van Haeringen, A., Moorman, A. F. M., Altherr, M. R., & den Dunnen, J. T. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.7.1071 · Cited by 308
A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3
Wang, Y., Spatz, M. K., Kannan, K., Hayk, H., Avivi, A., Gorivodsky, M., Pines, M., Yayon, A., Lonai, P., & Givol, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4455 · Cited by 228
Li, C. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.1.35 · Cited by 219
Cited by
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.007 · Cited by 2,443
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs
Chen, X., Li, A., Sun, B.-F., Yang, Y., Han, Y.-N., Yuan, X., Chen, R.-X., Wei, W.-S., Liu, Y., Gao, C.-C., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0361-y · Cited by 801
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
Gui, Y., Guo, G., Huang, Y., Hu, X., Tang, A., Gao, S., Wu, R., Chen, C., Li, X., Zhou, L., et al. (2011) · Nature Genetics · doi:10.1038/ng.907 · Cited by 747
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X.-R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1697 · Cited by 692
Seiwert, T. Y., Zuo, Z., Keck, M. K., Khattri, A., Pedamallu, C. S., Stricker, T., Brown, C., Pugh, T. J., Stojanov, P., Cho, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3310 · Cited by 657
Genomic complexity of multiple myeloma and its clinical implications
Manier, S., Salem, K. Z., Park, J., Landau, D. A., Getz, G., & Ghobrial, I. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.122 · Cited by 560
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
Billerey, C., Chopin, D., Aubriot-Lorton, M.-H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.-P., Lefrere-Belda, M.-A., Lahaye, J.-B., Abbou, C. C., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64665-2 · Cited by 498
Self-citationmTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Guo, G., Sun, X., Chen, C., Wu, S., Huang, P., Li, Z., Dean, M., Huang, Y., Jia, W., Zhou, Q., et al. (2013) · Nature Genetics · doi:10.1038/ng.2798 · Cited by 482
Guagnano, V., Furet, P., Spanka, C., Bordas, V., Le Douget, M., Stamm, C., Brueggen, J., Jensen, M. R., Schnell, C., Schmid, H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006222 · Cited by 477
Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer
Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., Edkins, S., Stevens, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1855 · Cited by 469
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
Brooks, A. N., Kilgour, E., & Smith, P. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0699 · Cited by 446
Gerstenfeld, L., Cho, T.-J., Kon, T., Aizawa, T., Tsay, A., Fitch, J., Barnes, G., Graves, D., & Einhorn, T. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.9.1584 · Cited by 434
Nogova, L., Sequist, L. V., Perez Garcia, J. M., Andre, F., Delord, J.-P., Hidalgo, M., Schellens, J. H. M., Cassier, P. A., Camidge, D. R., Schuler, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2048 · Cited by 432
Fibroblast growth factor signaling in tumorigenesis
Grose, R., & Dickson, C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.003 · Cited by 404
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080161 · Cited by 384
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 365
Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M. (2007) · The Journal of Pathology · doi:10.1002/path.2207 · Cited by 363
The role of fibroblast growth factors and their receptors in prostate cancer
Kwabi-Addo, B., Ozen, M., & Ittmann, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00535 · Cited by 350
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 347
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., & Knowles, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208705 · Cited by 340
Hernández, S., López-Knowles, E., Lloreta, J., Kogevinas, M., Amorós, A., Tardón, A., Carrato, A., Serra, C., Malats, N., & Real, F. X. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1771 · Cited by 334
van Rhijn, B. W. G., Vis, A. N., van der Kwast, T. H., Kirkels, W. J., Radvanyi, F., Ooms, E. C. M., Chopin, D. K., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.073 · Cited by 322
Self-citationRoles of Fibroblast Growth Factor Receptors in Carcinogenesis
Haugsten, E. M., Wiedlocha, A., Olsnes, S., & Wesche, J. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0168 · Cited by 315
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N., Kalyan, A., Matsangou, M., Costa, R., Carneiro, B., Villaflor, V. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14109 · Cited by 298
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
Chen, H., Ma, J., Li, W., Eliseenkova, A. V., Xu, C., Neubert, T. A., Miller, W. T., & Mohammadi, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.028 · Cited by 291
Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289
Allory, Y., Beukers, W., Sagrera, A., Flández, M., Marqués, M., Márquez, M., van der Keur, K. A., Dyrskjot, L., Lurkin, I., Vermeij, M., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.08.052 · Cited by 284
Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
Milacic, M., Haw, R., Rothfels, K., Wu, G., Croft, D., Hermjakob, H., D'Eustachio, P., & Stein, L. (2012) · Cancers · doi:10.3390/cancers4041180 · Cited by 280
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J. A., & Donoghue, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203650 · Cited by 276
Desnoyers, L. R., Pai, R., Ferrando, R. E., Hötzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 264
Achondroplasia: Development, pathogenesis, and therapy
Ornitz, D. M., & Legeai‐Mallet, L. (2017) · Developmental Dynamics · doi:10.1002/dvdy.24479 · Cited by 259
Role of Receptor Tyrosine Kinase Transmembrane Domains in Cell Signaling and Human Pathologies
Li, E., & Hristova, K. (2006) · Biochemistry · doi:10.1021/bi060609y · Cited by 258
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
Receptor tyrosine kinases as targets for anticancer drugs
Zwick, E., Bange, J., & Ullrich, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02217-1 · Cited by 252
Foldynova-Trantirkova, S., Wilcox, W. R., & Krejci, P. (2012) · Human Mutation · doi:10.1002/humu.21636 · Cited by 216
Goriely, A., Hansen, R. M. S., Taylor, I. B., Olesen, I. A., Jacobsen, G. K., McGowan, S. J., Pfeifer, S. P., McVean, G. A. T., Meyts, E. R.-D., & Wilkie, A. O. M. (2009) · Nature Genetics · doi:10.1038/ng.470 · Cited by 205
Nielsen, M. E., Smith, A. B., Meyer, A., Kuo, T., Tyree, S., Kim, W. Y., Milowsky, M. I., Pruthi, R. S., & Millikan, R. C. (2014) · Cancer · doi:10.1002/cncr.28397 · Cited by 149
MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors
Peter, M., Rosty, C., Couturier, J., Radvanyi, F., Teshima, H., & Sastre-Garau, X. (2006) · Oncogene · doi:10.1038/sj.onc.1209625 · Cited by 114
Self-citationAl‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2892 · Cited by 88
Xie, M., Zhou, L., Li, T., Lin, Y., Zhang, R., Zheng, X., Zeng, C., Zheng, L., Zhong, L., Huang, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202310146 · Cited by 18
Metadata
- Authors
- Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F.
- Venue
- Nature Genetics
- Published
- 1999-09
- Volume
- 23
- Issue
- 1
- Pages
- 18-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1563019250
- Cited by
- 713
- References
- 15
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.